Showing results (261-270 of 399) with videos related to

Sort By:
Pageof 40
Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.
Cancer Research|December 21, 2017
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase InhibitorsHideki Terai, Shunsuke Kitajima, Danielle S Potter, et al.
Research Square|February 26, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesVaradha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, et al.
Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.
The Journal of Clinical Investigation|November 4, 2014
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growthThanh U Barbie, Gabriela Alexe, Amir R Aref, et al.
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Lab on a Chip|September 6, 2018
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockadeAmir R Aref, Marco Campisi, Elena Ivanova, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.
Blood|February 28, 2014
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AMLSophia Adamia, Michal Bar-Natan, Benjamin Haibe-Kains, et al.
JAMA Oncology|October 24, 2024
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical TrialKartik Sehgal, Theodora Pappa, Kee-Young Shin, et al.
Pageof 40